>>AtheroGenics Announces New ARISE Diabetes Data on AGI-1067 Presented at the European Society of Cardiology Congress 2007
Wednesday September 5, 7:00 am ET
ATLANTA, GA--(MARKET WIRE)--Sep 5, 2007 -- AtheroGenics, Inc. (NasdaqGM:AGIX - News), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced the presentation of new scientific data from its ARISE Phase III clinical outcomes study of its lead oral anti-diabetic drug candidate, AGI-1067, at the European Society of Cardiology Congress 2007. The data were presented today by Marc A. Pfeffer, M.D., Ph.D., Professor of Medicine, Harvard Medical School, Cardiologist at Brigham and Women's Hospital, in a Hotline & Clinical Update session.
The data showed that at 12 months AGI-1067 significantly lowered levels of glycated hemoglobin A1c (A1c), a commonly used measure of glycemic control. There was greater improvement in A1c in subjects with higher baseline A1c levels. This effect was seen in patients with or without diabetes. In addition, the data showed a marked reduction of 59 percent (p < 0.0001) in the development of new onset diabetes in patients with impaired fasting glucose (IFG), a condition which is a precursor to diabetes. In patients with diabetes, treatment with AGI-1067 also demonstrated a 22 percent (p=0.062) reduction in hard cardiovascular events of cardiovascular death, cardiac arrest, myocardial infarction and stroke. AGI-1067 also led to a meaningful increase in kidney function as indicated by the estimated glomerular filtration rate (eGFR), an accepted measure of renal function.
"We believe that the unique mechanism of action for AGI-1067 may provide multiple therapeutic benefits for patients with diabetes," commented Rob Scott, M.D., Executive Vice President of Research & Development and Chief Medical Officer. "AtheroGenics is focused on the ANDES clinical trial to confirm the beneficial effect of AGI-1067 on glycemic control as the next step in clinical development for the agent."
Patient recruitment is currently underway in the Company's Phase III clinical trial called ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study) to study AGI-1067 as an oral therapy for the treatment of diabetes.<<
snip
Cheers, Tuck |
